BRPI1008663B8 - bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago - Google Patents

bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago

Info

Publication number
BRPI1008663B8
BRPI1008663B8 BRPI1008663A BRPI1008663A BRPI1008663B8 BR PI1008663 B8 BRPI1008663 B8 BR PI1008663B8 BR PI1008663 A BRPI1008663 A BR PI1008663A BR PI1008663 A BRPI1008663 A BR PI1008663A BR PI1008663 B8 BRPI1008663 B8 BR PI1008663B8
Authority
BR
Brazil
Prior art keywords
bacteriophage
pharmaceutical composition
diagnosing
genome
effective amount
Prior art date
Application number
BRPI1008663A
Other languages
English (en)
Inventor
Jorge Sousa De São José Carlos
Isabel Rodrigues Leandro Clara
Maria Rodrigues Pardal Dias Antunes Marçal Da Silva Filipa
Ângelo Da Costa Garcia Miguel
Ferreira Llorence Grancho Lourenço Sara
Original Assignee
Technophage Investig E Desenvolvimento Em Biotecnologia S A
Tecnifar Ind Tecnica Farmaceutica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technophage Investig E Desenvolvimento Em Biotecnologia S A, Tecnifar Ind Tecnica Farmaceutica S A filed Critical Technophage Investig E Desenvolvimento Em Biotecnologia S A
Publication of BRPI1008663A2 publication Critical patent/BRPI1008663A2/pt
Publication of BRPI1008663B1 publication Critical patent/BRPI1008663B1/pt
Publication of BRPI1008663B8 publication Critical patent/BRPI1008663B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

fagos antibacterianos, peptídeos fágicos e métodos de utilização dos mesmos a presente invenção é dirigida à área da terapia fágica para o tratamento e controlo de infecções bacterianas. em particular, a presente invenção é dirigida aos novos bacteriófados f1245/05, f168/08, f170/08, f770/05, f197/08, f86/06, f87s/06 e f91a/06, respectivos polipeptídeos isolados, composições compreendendo um ou mais dos novos bacteriófagos e/ou polipeptídeos isolados e métodos para o tratamento e prevenção de infecções bacterianas, isoladamente ou em combinação com outras terapias antibacterianas, por exemplo, antibióticos, ou outras terapias fágicas.
BRPI1008663A 2009-02-06 2010-02-05 bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago BRPI1008663B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15058509P 2009-02-06 2009-02-06
US61/150,585 2009-02-06
US21834509P 2009-06-18 2009-06-18
US61/218,345 2009-06-18
PCT/PT2010/000003 WO2010090542A2 (en) 2009-02-06 2010-02-05 Antibacterial phage, phage peptides and methods of use thereof

Publications (3)

Publication Number Publication Date
BRPI1008663A2 BRPI1008663A2 (pt) 2016-03-08
BRPI1008663B1 BRPI1008663B1 (pt) 2021-01-05
BRPI1008663B8 true BRPI1008663B8 (pt) 2021-10-05

Family

ID=42244489

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008663A BRPI1008663B8 (pt) 2009-02-06 2010-02-05 bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago

Country Status (14)

Country Link
US (2) US9134312B2 (pt)
EP (3) EP2393502B1 (pt)
JP (3) JP5701777B2 (pt)
CN (2) CN105456300B (pt)
AU (1) AU2010211456B2 (pt)
BR (1) BRPI1008663B8 (pt)
CA (2) CA2751641C (pt)
ES (2) ES2761835T3 (pt)
HK (1) HK1166956A1 (pt)
PL (1) PL3650034T3 (pt)
PT (1) PT3115054T (pt)
RU (2) RU2580248C9 (pt)
SG (3) SG173533A1 (pt)
WO (1) WO2010090542A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
US8840900B2 (en) * 2008-07-03 2014-09-23 The Rockefeller University Chimeric bacteriophage lysin with activity against Staphylococci bacteria
US20120276612A1 (en) * 2009-08-12 2012-11-01 Tzu Chi Buddhist General Hospital Phage of acinetobacter baumannii
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
CA2811472C (en) 2010-09-17 2019-08-27 Tecnifar-Industria Tecnica Farmaceutica, S.A. Antibacterial phage, phage peptides and methods of use thereof
KR101279780B1 (ko) 2011-10-05 2013-06-28 주식회사 인트론바이오테크놀로지 액티노바실러스 플루로뉴모니애에 대한 사멸능을 갖는 박테리오파지
PT2833899T (pt) * 2012-03-19 2020-09-15 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições compreendendo coquetéis de fagos e uso das mesmas para o tratamento de infeções bacterianas
CA3082772C (en) * 2012-05-04 2023-05-02 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
US9029319B1 (en) * 2014-08-04 2015-05-12 Centaur, Inc. Water buffalo derived peptide antibiotic therapies
EP3233099A1 (en) * 2014-12-17 2017-10-25 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Phage therapy for targeting enterococci
CN109206484B (zh) * 2015-11-20 2021-06-18 深圳市南山区人民医院 一种用于预防和治疗肠致病大肠杆菌感染的肽段
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
CN105648109B (zh) * 2016-01-08 2019-04-09 河南医学高等专科学校 一种噬菌体灭菌时化学抗菌剂筛选方法
CN106699862B (zh) * 2016-11-22 2020-06-09 中国科学院海洋研究所 三种来源于脊尾白虾alf的环状多肽及其应用和抗菌剂
CA3045284A1 (en) * 2016-12-05 2018-06-14 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
US10961276B2 (en) * 2017-02-17 2021-03-30 CAMRIS International, Inc. Universal antivenom
KR101957266B1 (ko) * 2017-02-22 2019-03-13 주식회사 인트론바이오테크놀로지 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
CN107365363B (zh) * 2017-09-20 2020-08-04 苏州大学 小分子多肽及其应用
CN107827955B (zh) * 2017-11-21 2020-05-29 苏州大学 源于分枝杆菌噬菌体多肽的衍生肽及其应用
WO2019176729A1 (ja) * 2018-03-12 2019-09-19 国立大学法人高知大学 新規バクテリオファージおよび細菌性眼内炎治療剤
WO2019224941A1 (ja) * 2018-05-23 2019-11-28 国立大学法人九州大学 食中毒細菌のバクテリオファージ耐性化抑制剤及びその使用
KR102131692B1 (ko) * 2018-09-11 2020-07-08 경북대학교 산학협력단 병원성 세균을 효과적으로 사멸시키는 재조합 항균 효소 LysSAP26의 용도
RU2703043C1 (ru) * 2018-09-20 2019-10-15 Наталия Петровна Антонова Литический фермент бактериофага и антибактериальная композиция на его основе
KR102193495B1 (ko) * 2018-12-26 2020-12-22 주식회사 옵티팜 신규한 아시네토박터 바우마니 균 특이 박테리오파지 ab63 및 이를 포함하는 항균 조성물
AU2020256258A1 (en) * 2019-04-05 2021-11-04 Contrafect Corporation Lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosa, in the presence of human serum
US20220211604A1 (en) * 2019-04-09 2022-07-07 Conopco, Inc., D/B/A Unilever Antimicrobial composition for selective lysis of s. hominis bacteria
RU2717972C1 (ru) * 2019-06-28 2020-03-27 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 324 (500318), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717026C1 (ru) * 2019-06-28 2020-03-17 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 325 (500319), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717451C1 (ru) * 2019-06-28 2020-03-23 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 323 (500317), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717973C1 (ru) * 2019-06-28 2020-03-27 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 322 (500316), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717435C1 (ru) * 2019-06-28 2020-03-23 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 326 (500320), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717420C1 (ru) * 2019-06-28 2020-03-23 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 327 (500321), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717022C1 (ru) * 2019-06-28 2020-03-17 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 328 (500322), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
CN110499266B (zh) * 2019-08-05 2021-04-27 昆明理工大学 一株粪肠球菌及其应用
US20210187046A1 (en) 2019-12-19 2021-06-24 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof
CN113214364B (zh) * 2020-01-21 2022-11-22 天津大学 一种多重耐药鲍曼不动杆菌识别元件的挖掘与验证
KR102604590B1 (ko) * 2020-09-28 2023-11-23 경북대학교 산학협력단 아시네토박터 바우마니에 대한 사멸능을 가지는 박테리오파지 및 이를 포함하는 조성물
CN116514934B (zh) * 2021-03-04 2024-04-30 西部(重庆)科学城种质创制大科学中心 抗CRISPR-Cas蛋白AcrIIIA1IME1367及其应用
WO2023113396A1 (ko) * 2021-12-14 2023-06-22 경북대학교 산학협력단 클로스트리듐 디피실 세균을 효과적으로 사멸시키는 재조합 항균 단백질의 용도
CN114703173B (zh) * 2022-03-18 2023-06-06 福建省农业科学院农业质量标准与检测技术研究所 一种λ噬菌体DNA提取试剂盒及提取方法
CN114807106B (zh) * 2022-04-25 2023-09-01 昆明市延安医院 一种裂解酶pEf51和穿孔素蛋白pEf191的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
GB9712663D0 (en) * 1997-06-16 1997-08-20 Borealis As Process
US20060292135A1 (en) * 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
AU4971900A (en) 1999-05-13 2000-12-05 Exponential Biotherapies, Inc. Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
ATE313341T1 (de) 2000-01-11 2006-01-15 Intralytix Inc Polymermischungen als bioabbaubare matrizen zur herstellung von biokompositen
RU2186574C1 (ru) * 2001-01-24 2002-08-10 Яфаев Рауэль Хасанянович Препарат поливалентного бактериофага против синегнойной палочки, штаммы бактериофага bacteriophagum pseudomonas aeruginosa спбгма им. и.и. мечникова №05, №03, №06 и №07, используемые при приготовлении поливалентного препарата против синегнойной палочки
DE60315636T2 (de) * 2002-03-25 2008-05-08 University Of Warwick, Coventry Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen
WO2004052274A2 (en) * 2002-12-09 2004-06-24 Phage Biopharm Llc Production of bacteriophage compositions for use in phage therapy
CN101003793A (zh) * 2007-01-11 2007-07-25 中国人民解放军第三军医大学 噬菌体对环境中致病菌的净化技术
PL215522B1 (pl) 2008-09-29 2013-12-31 Inst Immunologii I Terapii Doswiadczalnej Pan Nowe szczepy bakteriofagów do leczenia zakazen bakteryjnych, zwlaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
AU2009302985B2 (en) 2008-10-10 2015-09-10 Lusomedicamenta, S.A. Antibacterial phage peptides and methods of use thereof
KR20100093626A (ko) 2009-02-17 2010-08-26 서강대학교산학협력단 슈도모나스 애루지노사에 대한 파아지 치료
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o

Also Published As

Publication number Publication date
AU2010211456A1 (en) 2011-08-25
CN102348460B (zh) 2015-08-26
ES2761835T3 (es) 2020-05-21
EP3115054B1 (en) 2019-11-20
EP3650034C0 (en) 2023-09-20
CN105456300A (zh) 2016-04-06
RU2014127987A (ru) 2016-02-10
CA2751641C (en) 2018-11-13
US9134312B2 (en) 2015-09-15
BRPI1008663A2 (pt) 2016-03-08
RU2580248C9 (ru) 2018-01-17
US9682110B2 (en) 2017-06-20
BRPI1008663B1 (pt) 2021-01-05
US20160022747A1 (en) 2016-01-28
JP2012517225A (ja) 2012-08-02
RU2011134315A (ru) 2013-03-20
PL3650034T3 (pl) 2024-03-04
JP6177264B2 (ja) 2017-08-09
EP2393502A2 (en) 2011-12-14
EP3650034A1 (en) 2020-05-13
PT3115054T (pt) 2019-12-16
RU2580248C2 (ru) 2016-04-10
CN102348460A (zh) 2012-02-08
JP2017158568A (ja) 2017-09-14
EP2393502B1 (en) 2016-08-31
JP6355792B2 (ja) 2018-07-11
SG10201602330VA (en) 2016-04-28
EP3650034B1 (en) 2023-09-20
SG173533A1 (en) 2011-10-28
ES2963904T3 (es) 2024-04-03
EP3115054A1 (en) 2017-01-11
CA2751641A1 (en) 2010-08-12
JP5701777B2 (ja) 2015-04-15
AU2010211456B2 (en) 2016-05-26
WO2010090542A3 (en) 2010-12-23
JP2015154771A (ja) 2015-08-27
US20120052048A1 (en) 2012-03-01
WO2010090542A2 (en) 2010-08-12
CA3019013A1 (en) 2010-08-12
RU2671110C2 (ru) 2018-10-29
CN105456300B (zh) 2019-07-09
CA3019013C (en) 2020-12-15
HK1166956A1 (zh) 2012-11-16
SG2014012611A (en) 2014-07-30

Similar Documents

Publication Publication Date Title
BRPI1008663B8 (pt) bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago
Łusiak-Szelachowska et al. Bacteriophages and lysins in biofilm control
EP3443970A3 (en) Antibacterial phage, phage peptides and methods of use thereof
Høiby Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies
RU2014149351A (ru) Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
BRPI0616960B8 (pt) uso de lactobacilo para o tratamento de infecções virais
RU2020133461A (ru) Предотвращение, разрушение и обработка биопленки лизином бактериофага
BR112017004889A2 (pt) uso antibacteriano de salicilanilidas halogenadas
BRPI1012219C1 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BR112019011660A2 (pt) composições de bacteriófagos que compreendem fagos antibacterianos respiratórios e métodos de uso das mesmas
WO2015181356A8 (en) Vaccine composition against streptococcus suis infection
WO2010036876A3 (en) Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
BR112014023321A2 (pt) Composições compreendendo fagos antibacterianos e seus usos
BR112012025844A2 (pt) uso de nanofibras snag
WO2015089073A3 (en) Compositions and methods for phagocyte delivery of anti-staphylococcal agents
BR112015026773A2 (pt) cepas bacterianas que têm atividade antimicrobiana e composições de controle biológico que compreendem as mesmas
BR112013001577A2 (pt) conjugados de carboidrato e dihidorxiclorina e clorina <225>-funcionalizada e respectivos usos e método para eliminar microorganismos em ambiente de paciente real
Arsalan et al. Resistance pattern of clinical isolates involved in surgical site infections.
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
BR112022007926A2 (pt) Composições de cocktail que compreendem fagos antibacterianos respiratórios e métodos de utilização das mesmas
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
Sah et al. Skin and soft tissue infections: bacteriological profile and antibiotic resistance pattern of isolates
Brauers et al. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations
AU2018257122A1 (en) Pharmaceutical composition comprising attenuated streptococcus pneumoniae strains and use thereof
Yassin et al. Prevalence of metallo-β-lactamase producing Pseudomonas aeruginosa in wound infections in Duhok City, Iraq

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2370 DE 07/06/2016.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2609 DE 05/01/2021 QUANTO O INVENTOR (ITEM 72)

B25A Requested transfer of rights approved

Owner name: TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, S.A. (PT)